| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
we found that glp-1 analog liraglutide reduced er stress related gene expression in visceral fat cells accompanied by improved systemic insulin tolerance. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
consistently, glp-1 decreased chop expression and increased insulin stimulated akt phosphorylation (p-akt) in thapsigargin, a er stress inducer, treated white fat cells differentiated from visceral stromal vascular fraction. |
2020-10-01 |
2023-08-13 |
Not clear |
| Yaojing Jiang, Zhihong Wang, Bo Ma, Linling Fan, Na Yi, Bin Lu, Qinghua Wang, Rui Li. GLP-1 Improves Adipocyte Insulin Sensitivity Following Induction of Endoplasmic Reticulum Stress. Frontiers in pharmacology. vol 9. 2020-10-01. PMID:30459598. |
these findings suggest that glp-1 directly modulates the er stress response partially via inhibiting mtor signaling pathway, leading to increased insulin sensitivity in adipocytes. |
2020-10-01 |
2023-08-13 |
Not clear |
| Maria Kalogirou, Emmanouil Sinako. Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle? World journal of hepatology. vol 10. issue 11. 2020-10-01. PMID:30533179. |
glucagon-like peptide-1 (commonly known as glp-1) agonists are a novel class of antidiabetic drugs that improve insulin sensitivity and promote weight loss. |
2020-10-01 |
2023-08-13 |
Not clear |
| Kirk A Abraham, Monica L Kearney, Leryn J Reynolds, John P Thyfaul. Red wine enhances glucose-dependent insulinotropic peptide (GIP) and insulin responses in type 2 diabetes during an oral glucose tolerance test. Diabetology international. vol 7. issue 2. 2020-10-01. PMID:30603261. |
the purposes of this study were to evaluate the potential involvement of glucose-dependent insulinotropic peptide (gip) and glucagon-like peptide 1 (glp-1) in alcohol-induced augmentation of the insulin response and to determine if red wine acutely improves glucose tolerance during an oral glucose tolerance test (ogtt). |
2020-10-01 |
2023-08-13 |
Not clear |
| Dan Kawamor. Exploring the molecular mechanisms underlying α- and β-cell dysfunction in diabetes. Diabetology international. vol 8. issue 3. 2020-10-01. PMID:30603330. |
on the other hand, certain beneficial effects of glp-1 on dysfunctional α and β cells indicate that it has therapeutic potential for diabetes patients who exhibit insulin resistance in islets. |
2020-10-01 |
2023-08-13 |
mouse |
| Mari Cassol Ferreira, Maria Elizabeth Rossi da Silva, Rosa Tsuneshiro Fukui, Maria do Carmo Arruda-Marques, Salman Azhar, Rosa Ferreira Dos Santo. Effect of TCF7L2 polymorphism on pancreatic hormones after exenatide in type 2 diabetes. Diabetology & metabolic syndrome. vol 11. 2020-10-01. PMID:30700996. |
glucagon-like peptide 1 (glp-1) stimulates insulin secretion and reduces blood glucose in type 2 diabetes mellitus (t2dm). |
2020-10-01 |
2023-08-13 |
Not clear |
| Matthew D Stryker, Michael P Kane, Robert S Busc. A real-world, observational study of weekly exenatide added to basal insulin in patients with type 2 diabetes mellitus (NCT02895672). Endocrinology, diabetes & metabolism. vol 1. issue 1. 2020-10-01. PMID:30815541. |
this is a pre-post observational study from an endocrinology ambulatory care practice which assessed the effectiveness and safety following the addition of a glucagon-like peptide-1 (glp-1) agonist, weekly exenatide (bydureon), to basal insulin therapy in patients with type 2 diabetes mellitus (t2dm). |
2020-10-01 |
2023-08-13 |
Not clear |
| Mie Tonoike, Daisuke Chujo, Mitsuhiko Nod. Efficacy and safety of liraglutide added to insulin therapy in elderly patients with type 2 diabetes. Endocrinology, diabetes & metabolism. vol 2. issue 1. 2020-10-01. PMID:30815572. |
the combination of glp-1 receptor agonists and insulin is effective in type 2 diabetes (t2d) treatment. |
2020-10-01 |
2023-08-13 |
Not clear |
| Ida Bagus Aditya Nugraha, Made Ratna Saraswati, Ketut Suastik. The Pattern of Fasting and Post 75 G Glucose Loading of Glucagon-Like Peptide 1 Levels in Obese and Non-Obese Subjects. Open access Macedonian journal of medical sciences. vol 7. issue 3. 2020-10-01. PMID:30834001. |
reduced glucagon-like peptide 1 (glp-1) secretion is observed among obese subjects in many studies, and it may mediate the failure of insulin secretion response to food intake. |
2020-10-01 |
2023-08-13 |
human |
| Meryl Brod, Amaury Basse, Marie Markert, Kathryn M Pfeiffe. Post-Basal Insulin Intensification and Healthcare Resource Use in Type 2 Diabetes: A Web-Based Physician Survey in the United States and United Kingdom. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 10. issue 4. 2020-10-01. PMID:31127490. |
the purpose of the study was to investigate physicians' perspectives on the time and healthcare resources required for post-basal insulin intensification to basal-bolus and to basal in combination with a glucagon-like peptide-1 receptor agonist (glp-1) regimens. |
2020-10-01 |
2023-08-13 |
Not clear |
| Xiandong Zhan, Lijuan Wang, Zhenhui Wang, Shiping Chai, Xiaobo Zhu, Weidong Ren, Xiaotong Chan. High-glucose administration induces glucose intolerance in mice: a critical role of toll-like receptor 4. Journal of clinical biochemistry and nutrition. vol 64. issue 3. 2020-10-01. PMID:31138952. |
our results indicate that high-glucose load leads to glucose intolerance with insulin resistance through impairment of glp-1 secretion, increase of blood glucose levels via activating tlr4 and increasing levels of il-6 and tnf-α in mice. |
2020-10-01 |
2023-08-13 |
mouse |
| Neva Kandzija, Wei Zhang, Carolina Motta-Mejia, Vuyane Mhlomi, Jennifer McGowan-Downey, Tim James, Ana Sofia Cerdeira, Dionne Tannetta, Ian Sargent, Christopher W Redman, Claire C Bastie, Manu Vatis. Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus. Journal of extracellular vesicles. vol 8. issue 1. 2020-10-01. PMID:31164969. |
gestational diabetes mellitus (gdm) is the most common metabolic disorder in pregnancy and is characterized by insulin resistance and decreased circulating glucagon-like peptide-1 (glp-1). |
2020-10-01 |
2023-08-13 |
human |
| Neva Kandzija, Wei Zhang, Carolina Motta-Mejia, Vuyane Mhlomi, Jennifer McGowan-Downey, Tim James, Ana Sofia Cerdeira, Dionne Tannetta, Ian Sargent, Christopher W Redman, Claire C Bastie, Manu Vatis. Placental extracellular vesicles express active dipeptidyl peptidase IV; levels are increased in gestational diabetes mellitus. Journal of extracellular vesicles. vol 8. issue 1. 2020-10-01. PMID:31164969. |
dipeptidyl peptidase iv (dppiv) is known to play a role in type 2 diabetes by breaking down glp-1, which in turn regulates glucose-dependent insulin secretion. |
2020-10-01 |
2023-08-13 |
human |
| Shian-Ren Lin, Chia-Hsiang Chang, May-Jwan Tsai, Henrich Cheng, Jian-Chyi Chen, Max K Leong, Ching-Feng Wen. The perceptions of natural compounds against dipeptidyl peptidase 4 in diabetes: from Therapeutic advances in chronic disease. vol 10. 2020-10-01. PMID:31555430. |
in diabetic use, the dpp-4 inhibitor can block the ddp-4 to attenuate glp-1 degradation and prolong glp-1 its action and sensitize insulin activity for the purpose of lowering blood glucose. |
2020-10-01 |
2023-08-13 |
Not clear |
| Jin Ah Ryuk, Suna Kang, James W Daily, Byoung-Seob Ko, Sunmin Par. Moderate intake of aspartame and sucralose with meals, but not fructose, does not exacerbate energy and glucose metabolism in estrogen-deficient rats. Journal of clinical biochemistry and nutrition. vol 65. issue 3. 2020-10-01. PMID:31777424. |
postprandial serum glucagon-like peptide-1 (glp-1) and insulin levels were higher in aspartame and sucralose than control. |
2020-10-01 |
2023-08-13 |
human |
| Jixin Zhong, Andrei Maiseyeu, Sanjay Rajagopala. Lipoprotein effects of incretin analogs and dipeptidyl peptidase 4 inhibitors. Clinical lipidology. vol 10. issue 1. 2020-09-30. PMID:26005496. |
the incretins glucagon like peptide-1 (glp-1) and glucose insulinotropic peptide (gip) modulate post-prandial lipoproteins through a multitude of pathways that are independent of insulin and weight loss. |
2020-09-30 |
2023-08-13 |
human |
| Barnaby Hunt, Divina Glah, Maarten van der Vlie. Modeling the Long-Term Cost-Effectiveness of IDegLira in Patients with Type 2 Diabetes Who are Failing To Meet Glycemic Targets on Basal Insulin Alone in The Netherlands. Diabetes therapy : research, treatment and education of diabetes and related disorders. vol 8. issue 4. 2020-09-30. PMID:28523483. |
insulin degludec/liraglutide (ideglira) is the first basal insulin and glucagon-like peptide-1 receptor agonist (glp-1 ra) in a single pen injection device, and a once-daily treatment option for patients with type 2 diabetes mellitus (t2dm) who are uncontrolled on basal insulin and require treatment intensification. |
2020-09-30 |
2023-08-13 |
Not clear |
| B Laferrèr. Bariatric surgery and obesity: influence on the incretins. International journal of obesity supplements. vol 6. issue Suppl 1. 2020-09-30. PMID:28685028. |
the improvement in insulin secretion rate and β-cell sensitivity to oral glucose after rygbp is mediated by endogenous glp-1, and is abolished by exendin 9-39, a specific glp-1 receptor antagonist. |
2020-09-30 |
2023-08-13 |
Not clear |
| Kohzo Takebayashi, Toshihiko Inuka. Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus. Journal of clinical medicine research. vol 9. issue 9. 2020-09-30. PMID:28811850. |
recent evidence shows that these sglt2 inhibitors with low sglt2/sglt1 selectivity elevate the level of circulating glucagon like peptide-1 (glp-1), an incretin hormone that promotes insulin secretion in pancreatic β cells. |
2020-09-30 |
2023-08-13 |
Not clear |